Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Veronique Dieras, Florence Dalenc, Jennifer Robinson Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O'Shaughnessy, Sibylle Loibl, Luca Gianni, Martine J. Piccart-Gebhart, Quan Hong, Martin Sebastian Olivo, Loretta Itri, Javier Cortes
Institutions: UNC Lineberger Comprehensive Cancer Center, Institut Curie, Universitair Ziekenhuis Leuven, Harvard University, Massachusetts General Hospital, Centre Eugène Marquis, Institut universitaire du cancer de Toulouse Oncopole, Institut Claudius Regaud, University of Colorado Anschutz, Universitair Ziekenhuis Brussel, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Emory University, Winship Cancer Institute, Université Libre de Bruxelles, Institut Jules Bordet, Immunomedics (United States), IDCQ Hospitales y Sanidad, S.L.U.
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3169907277